SCHEMBL5094475

SCHEMBL5094475

CCOC(=O)C(=CN(c1ccccc1)c1ccccc1)C(=O)OCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.60
KMT2A Q03164 6/20 0.60
MAPT P10636 6/20 0.51
GAA P10253 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
DHODH Q02127 3/20 0.48
LMNA P02545 3/20 0.48
PLIN1 O60240 1/20 0.48
POLB P06746 1/20 0.48
PLIN5 Q00G26 1/20 0.48
ABHD5 Q8WTS1 1/20 0.48
TSHR P16473 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 2/20 0.45
NPSR1 Q6W5P4 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
S1PR4 O95977 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5089790 0.85 MEN1 (0.58) MEN1KMT2AMAPTGAATDP1
SCHEMBL5768033 0.83 MEN1 (0.55) MEN1KMT2AMAPTGAATDP1
SCHEMBL398239 0.81 MEN1 (0.54) MEN1KMT2AMAPTGAATDP1
SCHEMBL19041226 0.80 ALDH1A1 (0.47) MEN1KMT2AMAPTGAATDP1
SCHEMBL9094971 0.78 MEN1 (0.54) MEN1KMT2AMAPTGAATDP1
SCHEMBL9094974 0.78 MEN1 (0.54) MEN1KMT2AMAPTGAATDP1
SCHEMBL11281728 0.78 MEN1 (0.50) MEN1KMT2AMAPTGAATDP1
SCHEMBL11272186 0.78 MEN1 (0.50) MEN1KMT2AMAPTGAATDP1
SCHEMBL10861409 0.76 KMT2A (0.55) MEN1KMT2AMAPTGAATDP1
SCHEMBL10868370 0.76 MEN1 (0.48) MEN1KMT2AMAPTGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7339061-B2 3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2008-03-04 US disclosed
US-20060063801-A1 Novel 3-(4-oxo-4h-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063801-A1 Novel 3-(4-oxo-4h-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, RB1 MEN1 2547/4885KMT2A 2942/4885MAPT 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.